The conversation discusses a new study on topical pumpkin seed oil for hair loss in mice. Treatments mentioned include Minoxidil, finasteride, and RU58841.
The user is applying topical finasteride with stemoxydine for hair loss and has noticed hair thickening but no regrowth after two months. They also report high SHBG and prolactin levels and a lack of morning erections, even on low doses of medication.
The user experienced side effects from oral finasteride and tried mixing it with liquid minoxidil but faced application issues. They are seeking a 5% minoxidil foam with a maximum of 0.15% topical finasteride concentration.
A user is taking 1 mg finasteride daily with nanoxidil and wants to know how to mix finasteride tablets into a 60 ml nanoxidil bottle for topical use. They are concerned about side effects and considering switching to topical finasteride.
The conversation confirms that to make a 5% RU58841 solution, 1.5 grams should be added to 30 mL of KB Solution. The discussion involves calculating the correct dosage for hair loss treatment.
Pelage Pharmaceuticals received $120 million in Series B funding for hair loss treatment development. The conversation expresses excitement and anticipation for the release and effectiveness of the treatment.
Latisse (bimatoprost) is discussed as a potential treatment for hair growth due to difficulty obtaining PGE2. Users also mention concerns about sourcing reliable products from China.
A user with diffuse thinning recommends a root cover-up spray as a temporary, medication-free solution. They plan to consult a dermatologist for treatments like Minoxidil and finasteride while using the spray for special occasions.
People who experience diffuse thinning of their hair and how they cope with going swimming. People discussed wearing a swimming cap, making jokes out of it and accepting that it's genetics.
A user is using a topical spray containing Finasteride 1% and Minoxidil 5% along with other ingredients like glycerin and aqua, questioning if these are effective carrier agents. They apply it once daily and use a separate 5% Minoxidil solution at night.
PP405 is being discussed as a potential new approach to hair loss by targeting follicle stem cells, suggesting a different mechanism from existing treatments like finasteride and minoxidil. However, there is skepticism about whether it will lead to meaningful long-term outcomes or follow the pattern of previous treatments that showed promise but lacked consistent results.
The user is using a hair loss treatment with finasteride 0.1%, minoxidil 5%, and tretinoin 0.01%, applied once daily at 1ml. They are questioning if a 60ml bottle used twice daily implies a higher recommended dose despite the same 5% minoxidil concentration.
Minoxidil may age skin by slowing collagen synthesis, but using collagen peptides and a basic skincare routine might counteract this. Foam minoxidil could reduce systemic absorption and avoid alcohol-related side effects.
Foam minoxidil may be a good alternative for those who experience irritation from liquid minoxidil, though opinions on its effectiveness vary. Some users suggest oral minoxidil as a more effective option with fewer side effects at low doses, while others recommend foam or alcohol-free topical versions for sensitive scalps.
Users discuss making topical finasteride solutions by dissolving crushed tablets in ethanol and propylene glycol, with concerns about residue affecting effectiveness. They also mention using minoxidil and oral finasteride, noting some hair regrowth and no side effects from topical use.
The conversation humorously discusses using off-label drugs like Minoxidil, finasteride, and RU58841 for hair growth. It jokes about the brain absorbing these treatments for maximum keratin production.
The conversation is about compounding topical cyclosporine for hair loss, suggesting it needs an oil base like castor oil. The user seeks tips or tricks for the process.
Using a microdose of finasteride on the scalp with minoxidil as a carrier may have positive effects with minimal side effects. The user is also considering the effects of sulforaphane or broccoli sprouts on hair loss.
Rotenone, a natural plant extract, may promote hair growth by increasing LDH activity and blocking MPC in the scalp, but it carries risks due to its toxicity. The suggested formulation includes Barbasco extract, DMSO, propylene glycol or PEG-400, ethanol, and a carrier oil.
User is using a homemade topical treatment with .015% finasteride, 5% minoxidil, and microneedling at .75mm depth. They also use 2% ketoconazole shampoo, various oils, and are considering increasing finasteride concentration due to mixed results.
Microneedling depth should be customized based on hair type and scalp area, with many users finding 0.5-0.6mm effective for miniaturized hairs to avoid damage. Users report varying pain levels and results, with some preferring shorter needle lengths and others using longer ones like 1.75mm for scalp health and density improvement.
Topical finasteride and minoxidil are not effective for the user, who is considering switching to oral treatments like finasteride or dutasteride. Many suggest oral medications are more effective, and some recommend additional treatments like microneedling and other topical solutions.
The conversation discusses switching from topical to oral Minoxidil for hair loss treatment, with the expectation of better results due to systemic delivery. The user has been using Finasteride, topical Minoxidil, and dermastamping, maintaining hair but seeking more regrowth.
A satirical discussion on using minoxidil and finasteride in unconventional ways, including mixing them into drinks and other humorous methods. The conversation also touches on the potential health risks of minoxidil.
Hair regrowth treatments are effective in mice but not yet available for humans. The discussion humorously highlights frustration over this disparity and mentions a project to genetically modify elephants to resemble mammoths.
The conversation discusses Breezula, a hair loss treatment, and its Phase 3 clinical trial recruitment at 50 locations. Specific treatments mentioned include Minoxidil, Finasteride, and RU58841.
The conversation discusses the safety study of PP405, emphasizing that early trials focus on safety rather than efficacy, and that any efficacy data from such a short study should be viewed skeptically. It also highlights that the information released is primarily for securing funding, and that meaningful efficacy results are expected in later phases.